vonaprument

**vonaprument** is a first-in-class, non-pegylated antigen-binding fragment (Fab) monoclonal antibody designed to selectively inhibit C1q, the initiating molecule of the classical complement pathway, with a neuroprotective effect relevant in age-related macular degeneration (AMD)[1]. It is administered intravitreally and is intended to preserve vision in patients with advanced dry AMD complicated by geographic atrophy (GA). \nvonaprument is notable for being the only investigational therapy for dry AMD with GA to demonstrate significant vision preservation in clinical trials, based on best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA)[1][4]. The drug is being developed by Annexon and is currently in Phase 3 clinical trials, with topline data expected in the second half of 2026[1][2]. \nTherapy developed by: Annexon

Other names

Anti-C1q therapyAnti-C-1q therapyAnti-C 1q therapy